

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Serial No.:	10/567,114	Confirmation No.:	2900
Applicant(s):	ZHILOV, et al.	Group Art Unit:	T/B/A
Examiner:		T/B/A	
Filed:	August 4, 2003	Customer No.:	27123
For:	CYCLIC BIOISOSTERS OF PURINE SYSTEM DERIVATIVES AND A PHARMACEUTICAL COMPOSITION		

**REPLACEMENT INFORMATION DISCLOSURE STATEMENT**

Mail Stop \_\_\_\_\_  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Sir:


Pursuant to Rule 56, applicant hereby calls the attention of the Patent Office to the references listed on the attached Form PTO 1449. This Replacement Information Disclosure Statement (IDS) is being submitted to replace the IDS filed via EFS – ID No. 1281787 on November 1, 2006. Listings on the Form PTO 1449 of that filing were inadvertently omitted.

Copy(ies) of these references:

- Foreign Patent Applications, Foreign Patents and/or Other Non-Patent Documents are attached (Copies of cited U.S. Patents/Publications are not provided).
- Were filed in related application U.S. Serial No(s) \_\_\_\_\_, filed \_\_\_\_\_, respectively.
- This document is being filed within three (3) months of the filing date of the application
- A check for the requisite fee of \$180 is enclosed.
- This document is being concurrently filed with the above-identified application
- This document is being concurrently filed with an Request for Continued Examination (RCE)
- This document is being filed prior to a first Office Action
- This document is accompanied by a Search Report/Communication cited in a corresponding PCT or foreign counterpart application.
- The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. **13-4500**, Order No. **4874-7000**. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,  
 MORGAN & FINNEGAN, L.L.P.

By:



Eric G. Wright  
 Registration No. 48,045

Dated: November 2, 2006**Correspondence Address:**

MORGAN & FINNEGAN, L.L.P.  
 3 World Financial Center  
 New York, NY 10281-2101  
 (212) 415-8700 Telephone  
 (212) 415-8701 Facsimile

<b>FORM PTO-1449A</b> <b>INFORMATION DISCLOSURE CITATION</b>		Attorney Docket: 4874-7000	Serial No.: 10/567,114
		Applicant: ZHILOV, et al.	
		Filing Date: August 4, 2003	Group Art Unit: T/B/A

**U.S. PATENT / PUBLICATION DOCUMENTS**

Examiner Initial	Patent/Publication Number	Publication/Issue Date	Name	Filing Date
1.				
2.				
3.				
4.				
5.				
6.				
7.				
8.				
9.				
10.				
11.				
12.				
13.				
14.				

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Patent Number	Publication Date	Country	Copy Filed	Translation
/J.L./	15. 2014077 C1	06-15-1994	Russia	<input checked="" type="checkbox"/> Yes	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	16.			<input type="checkbox"/> Yes	<input type="checkbox"/> Yes <input type="checkbox"/> No
	17.			<input type="checkbox"/> Yes	<input type="checkbox"/> Yes <input type="checkbox"/> No
	18.			<input type="checkbox"/> Yes	<input type="checkbox"/> Yes <input type="checkbox"/> No
	19.			<input type="checkbox"/> Yes	<input type="checkbox"/> Yes <input type="checkbox"/> No
	20.			<input type="checkbox"/> Yes	<input type="checkbox"/> Yes <input type="checkbox"/> No

Examiner	/Jonathan Lau/	Date Considered	07/02/2009
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

<b>FORM PTO-1449B</b>		Attorney Docket: 4874-7000	Serial No.: 10/567,114
<b>INFORMATION DISCLOSURE CITATION</b>		Applicant: ZHILOV, et al.	
		Filing Date: August 4, 2003	Group Art Unit: T/B/A

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/J.L./	1.	Trump B.F., Berezesky I.K. "The role of altered [Ca <sup>2+</sup> ] in regulation in apoptosis, oncosis and necrosis". Biochem. Biophys. Acta, 1996, v. 1313, p. 173-178.
	2.	Roos A., Boron W.F. "Intracellular pH". Physiol. Rev., 1981, v. 61, p. 296-434.
	3.	Akutow V.S., Grobova M.E., Rkshevoi Yu.V. "Intracellular pH and substrate dependence of proliferation of fibroblasts of Chinese hamster". Cytology, 1991, 33 (7), p. 86-94.
	4.	Gillies R.G., Martinez-Zaguilan R., Peterson E.P., Perona R. "The role of intracellular pH in mammalian cell proliferation". Cell. Physiol. Biochem., 1992, 2, p.159-179.
	5.	Akutow V.S., Grobova M.E. "Activation of intracellular pH regulating systems upon cell adhesion to solid substrate". Biol. Membr., 1993, v.6, p. 917-934.
	6.	Kapus A., Romanek R., Qu A.Y., Rotstein O.O., Grinstein S.A. "pH-sensitive and voltage-dependent proton conductance in the plasma membrane of macrofages". J. Gen. Physiol., 1993, vol. 02 (4), p. 723-760.
	7.	Demaurex N., Downey G., Waddell T., Grinstein S. "Intracellular pH regulator during spreading of human neutrophils", J.Cell. Biol., 1996, v. 133, p. 1381-1402.
	8.	Tannock I.A., Rotin D. "Acid pH in tumors and its potential for therapeutic exploration". Cancer Res., 1989, v.49, p. 4373-4384.
	9.	Stabbs M., Rodrigues L., Howl F.A., Wang I., Joeng K.S., Veech R.L., Griffiths J.R. "Metabolic consequences of a reversed pH gradient in rat tumors". Cancer Res., 1994, v.54, p. 4011-4016.
↓	10.	Mashkovsky M.D., "Medicinal Agents". Moscow, Medicine, 1993, part II, p. 137-140.
/J.L./	11.	Taguchi Hiroshi. "A new fluorometric assay method for guinolinic acid". Analitic Biochemistry, 1983, 131 (1), p. 194-197

Examiner Signature	/Jonathan Lau/	Date Considered	07/02/2009
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<b>FORM PTO-1449B</b>		Attorney Docket: 4874-7000	Serial No.: 10/567,114
<b>INFORMATION DISCLOSURE CITATION</b>		Applicant: <u>ZHILOV, et al.</u>	
		Filing Date: August 4, 2003	Group Art Unit: T/B/A

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/J.L./	12.	Huntress E.H., Stanley L.N., Parker A.S. "The preparation of 3-Aminophthalhydrazide for use in the Demonstration of Chemiluminescence", J. Am. Chem. Soc., 1994, v. 56, p. 241-242.
	13.	Zyczynska - Baloniak I., Czajka R., Zinkowska E., "Synthesis of Derivatives of 4-Hydroxypyrazine-[2,3-d]pyridazine-1-one. Polish Journal of Chemistry. 1978, v. 52, p. 2461-2465.
	14.	Kormendy K., Ruff F. "Pyridazines condensed with a Heteroring. III", Acta Chimica Hungarica. 1990, 127 (2), p. 253-262.
	15.	Yurugi S., Hieda M. "Studies on the synthesis of N- Heterocyclic Compounds". Chemistry, Pharmaceutic Bull., 1972, v. 20 (7), p 1522-1527. ibid., p. 1513-1521.
	16.	Seo E., Kuwana T. "Polarography of cyclic Hydrazides", J. Electroanal. Chem., 1963, v. 6, p. 417-418.
	17.	Lund H. "Polarographic and electropreparative reduction of 1(2H)-phthalazines, 2,3-dihydro-1,4 phthalazindiones and related compounds", Coll. Czechoslow. Chem.Com., 1965, v. 30. p. 4237-4249.
↓	18.	Ganz M.B. et al. "Argininvasopression enhancers of pH, regulation in the presence of HCO <sub>3</sub> <sup>-</sup> by stimulating three acid-base transport systems", Nature, 1989, v. 337, p. 648-651.
/J.L./	19.	Rogachev B., Hausmann M.J., Julzari R., Weiler H., Holmes C., Falct D., Chairmovitz C., Douvdevani A. "Effect of bicarbonat-based dialysis solution on intracellular pH (pH <sub>i</sub> ) and TNF-alpha production by peritoneal macrophages, Perit. Dial. Int., 1997, Nov-Dec, 17 (6), p. 543-553.

Examiner Signature	/Jonathan Lau/	Date Considered	07/02/2009
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<b>FORM PTO-1449B</b>  <b>INFORMATION DISCLOSURE CITATION</b>		Attorney Docket: 4874-7000	Serial No.: 10/567,114
<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
/J.L./	20.	Bidani A., Heming T.A. "Effect of concanavalin A on Na <sup>+</sup> -dependent and Na <sup>+</sup> -independent mechanism for H <sup>+</sup> extrusion in alveolar macrophages", Lung., 1998, 176 (1), p. 25-31.	
/J.L./	21.	Swallow C.J., Grinstein S., Sudsbury R.A., Rotstein O.D. "Relative roles of Na <sup>+/H<sup>+</sup></sup> exchange and vacuolar-type H <sup>+</sup> ATPases in regulating cytoplasmic pH and Function in murine peritoneal macrophages", J. Cell. Physiol., 1993, 157 (3), p. 453-460.	
/J.L./	22.	Koshevoi Yu.V., Akatov V.S., Grobova M.E., "Microspectrofluorimeter for measuring endocellular pH (micro pH)". Devices and equipment for studies in the field of physical-and-chemical biology and biotechnology. Pushchino, 1990. P. 8-14.	
/J.L./	23.	Thomas J.A., Bushbaum R.N., Zimniak A.w Racker E. "Intracellular pH measurements in Ehrlich ascites tumor cells utilizing spectroscopic probe generated <i>in situ</i> ", Biochemistry, 1979, v. 18, p. 2210-2218.	
/J.L./	24.	Li J., Eastman A. "Apoptosis in an interleukin-2-dependent cytotoxic T-lymphocyte cell line is associated with intracellular acidification", J.Biol. Chem., 1995, v. 270 , Number 7, p. 3203-3211.	
/J.L./	25.	Solovieva M.E., Akatov V.S., Leshchenko V.V., Kudryavtsev V.A. "The mechanism of destruction of cells of myeloma NS/O in culture". Proceeding of the Russian Academy of Sciences, 1998, 2, p. 194-189.	
/J.L./	26.	Zhu W.-H., Loh T.-T. "Effects of Na <sup>+</sup> /H <sup>+</sup> antiport and intracellular pH in the regulation of HL-60 cell apoptosis", Biochim. Biophys. Acta, 1995, v. 1269, p. 122-128.	
Examiner Signature	/Jonathan Lau/		Date Considered 07/02/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<b>FORM PTO-1449B</b>		<b>Attorney Docket:</b> 4874-7000	<b>Serial No.:</b> 10/567,114
<b>INFORMATION DISCLOSURE CITATION</b>		<b>Applicant:</b> ZHILOV, et al.	
		<b>Filing Date:</b> August 4, 2003	<b>Group Art Unit:</b> T/B/A
<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	

/J.L./	27.	Brenton P.D. "Mechanistic Aspect of Diazaquinone Chemiluminescence", Aust. J. Chem., 1984, v. 37, p. 1001-1008.
	28.	Nishikimi M. Rao N.A. and Yagi K. "The occurrence of superoxide anion in the reaction of reduced phenasine methosulfate and molecular oxygen". Biochem. Biophys. Res. Commun., 1972, v. 46, p. 849-855.
	29.	Rahman S., Ali Khan R., Kumar A. "Experimental study of the morphine deaddiction properties of Delphinium nududatum Wall/BMC Complement Altern". Med. 2002, v. 29, p. 1-6.
	30.	Dum J., Blasig J., Herz A. Buprenorphine: "Demonstration of physical dependence liability". Eur. J. Pharmacol., 1981, v. 70. p. 293-300.
	31.	Misko T.R., Schilling R.J., Salvemini D. et al. "A fluorometric assay for the measurement of nitrite of biological samples". Anal. Biochem., 1993, v. 214, p. 11-16.
	32.	Bredt and Snyder. "Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum". Proc. Natl. Acad. Sci. USA, 1989, v. 86, p. 9030-9033.
	33.	Kiss J.P., Vizi E.S., "Nitric oxide: a novel link between synaptic and nonsynaptic transmission," Trends Neurosci., 2001, Apr., 24 (4):211-5.
	34.	Paul I.A., Skolnick P., "Glutamate and depression: clinical and preclinical studies," Ann. N Y Acad. Sci., 2003, Nov; 1003:250-72.
	35.	Girgin Sagin F., Sozmen E.Y., Ersoz B., Mentes G., "Link between monoamine oxidase and nitric oxide," Neurotoxicology, 2004, Jan., 25 (1-2): 91-9.
/J.L./	36.	Vizi E.S., "Role of high-affinity receptors and membrane transporters in nonsynaptic

Examiner Signature	/Jonathan Lau/	Date Considered	
--------------------	----------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<b>FORM PTO-1449B</b>		Attorney Docket: 4874-7000	Serial No.: 10/567,114
<b>INFORMATION DISCLOSURE CITATION</b>		Applicant: ZHILOV, et al.	
		Filing Date: August 4, 2003	Group Art Unit: T/B/A
<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
/J.L./	36. (cont)	communication and drug action in the central nervous system," Pharmacol. Rev., 2000, Mar., 52 (1): 63-89.	
	37.	Liu Y., "Nitric oxide effect dopaminergic processes", Adv. Neuroimmunol., 1996, 6 (3): 259-64.	
	38.	Chiavegatto S., Nelson R.J., "Interaction of nitric oxide and serotonin in aggressive behavior," Horm. Behav., 2003, Sep., 44 (3): 233-41.	
	39.	Pfaus J.G., "Neurobiology of sexual behavior", Curr. Opin. Neurobiol., 1999, Dec., 9 (6): 751-8.	
	40.	Stefano G.B., "Autoimmunovascular regulation: morphine and anandamide and anandamide stimulated nitric oxide release", J.Neuroimmunol., 1998, Mar., 15, 83 (1-2): 70-6.	
	41.	Tayfun Uzbay I., "Oglesby M.W. Nitric oxide and substance dependence," Neurosci. Biobehav. Rev., 2001, Jan., 25 (1): 43-52.	
	42.	Kiss J.P. "Role of nitric oxide in the regulation of monoaminergic neurotransmission", Brain Res. Bull., 2000, Aug., 52 (6): 459-66.	
	43.	Mandel S., Grunblatt E., Riederer P., Gerlach M., Levites Y., "Yousdim M.B. Neuroprotective strategies in Parkinson's disease: an update on progress", CNS Drugs, 2003, 17 (10): 729-62.	
↓	44.	Ujike H., "Advanced findings on the molecular mechanisms for behavioral sensitization to psychostimulants", Nippon Yakurigaku Zasshi., 2001, Jan., 117 (1): 5-12.	
/J.L./	45.	Olesen J., Jansen-Olesen I., "Nitric oxide mechanisms in migraine." Pathol. Biol., Paris, 2000, Sep., 48 (7): 648-57.	
Examiner Signature	/Jonathan Lau/	Date Considered	07/02/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 800. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant. 1 Applicant's unique citation identification number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.57 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is guaranteed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application forms to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<b>FORM PTO-1449B</b>  <b>INFORMATION DISCLOSURE CITATION</b>		Attorney Docket: 4874-7000	Serial No.: 10/567,114
		Applicant: ZHILOV, et al.	
		Filing Date: August 4, 2003	Group Art Unit: T/B/A
<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
/J.L./	46.	Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G., "Dopamine receptors: from structure to function", <i>Physiol. Rev.</i> , 1998, Jan., 78 (1): 189-225.	
	47.	Zawilska J.B. "Dopamine receptors-structure, characterization and function", <i>Postepy Hig. Med. Dosw.</i> , 2003, 57 (3): 293-322.	
	48.	Fagen Z.M., Mansvelder H.D., Keath J.R., Mc. Gehee D.S., "Short- and long-term modulation of synaptic inputs to brain reward areas by nicotine", <i>Ann. NY Acad. Sci.</i> , 2003, Nov., 1003: 185-95.	
	49.	Ujike H., "Molecular biology of drug dependence and behavioral sensitization", <i>Seishin Shinkeigaku Zasshi.</i> , 2002, 104 (11): 1055-68.	
	50.	Wolf M.E., Mangiavacchi S., Sun X., "Mechanisms by which dopamine receptors may effect synaptic plasticity", <i>Ann. NY Acad. Sci.</i> , 2003, Nov., 1003: 241-9.	
	51.	Kosten T.R., George T.P., Kosten T.A., "The potential of dopamine agonists in drug addiction", <i>Expert Opin. Investig. Drugs</i> , 2002, Apr., 11 (4): 491-9.	
	52.	Pearson G.D. "Neurobiology of schizophrenia", <i>Ann. Neurol.</i> , 2000, Oct., 48 (4): 556-66.	
	53.	Abi-Dargham A., Moore H., "Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia", <i>Neuroscientist</i> , 2003, Oct., 9 (5): 404-16.	
	54.	Conley R.R., Kelly D.L. "Current status of antipsychotic treatment" <i>Curr. Drug Target CNS. Neurol. Disord.</i> , 2002, Apr., 1 (2): 123-8.	
/J.L./	55.	Taylor D.P., Riblet L.A., Stanton H.C., Eison A.S., Eison M.S., Temple DL Jr.. "Dopamine and antianxiety activity", <i>Pharmacol. Biochem. Behav.</i> , 1982, 17, Suppl. 1: 25-35.	

Examiner Signature	/Jonathan Lau/	Date Considered	07/02/2009
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant to place a check mark here if English language Translation is attached. The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to be paid by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form, and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<b>FORM PTO-1449B</b>		Attorney Docket: 4874-7000	Serial No.: 10/567,114
<b>INFORMATION DISCLOSURE CITATION</b>		Applicant: <u>ZHILOV, et al.</u>	
		Filing Date: August 4, 2003	Group Art Unit: T/B/A
<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	

/J.L./	56.	Kapur S., Mamo D. "Half a century of antipsychotics and still a central role for dopamine D2 receptors", <i>Prog. Neuropsychopharmacol. Biol. Psychiatry</i> , 2003, Oct., 27 (7): 1081-90.	
		Taguchi Hiroshi. "A new fluorometric assay method for quinolinic acid". <i>Analitic Biochemistry</i> , 1983, 131 (1), p. 194-197.	
	57.	Huntress E.H., Stanley L.N., Parker A.S. "The preparation of 3-Aminophthalhydrazide for use in the Demonstration of Chemiluminescence", <i>J. Am. Chem. Soc.</i> , 1994, v. 56, p. 241-242.	
		Zyczynska - Baloniak I., Czajka R., Zinkowska E., "Synthesis of Derivatives of 4-Hydroxypyrazine-[2,3-d]pyridazine-1-one. Polish Journal of Chemistry. 1978, v. 52, p. 2461-2465.	
	58.	Kormendy K., Ruff F. "Pyridazines condensed with a Heteroring. III", <i>Acta Chimica Hungarica</i> . 1990, 127 (2), p. 253-262.	
		Yurugi S., Hieda M. "Studies on the synthesis of N- Heterocyclic Compounds". <i>Chemistry, Pharmaceutic Bull.</i> , 1972, v. 20 (7), p 1522-1527. <i>ibid.</i> , p. 1513-1521.	
	60.	Dum J., Blasig J., Herz A., "Buprenorphine: demonstration of physical dependence liability", <i>Eur. J. Pharmacol.</i> , 1981, V. 70, p. 293-300.	
		Rahman S., Ali Khan R., Kumar A., "Experimental study of the morphine de-addiction properties of Delphinium denudatum Wall", <i>BMC Complement Altern. Med.</i> , 2002, V.29, p.1-6.	
↓	63.	Blasig J., Herz A., Reinhold K., Zieglgansberger S. "Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats", <i>Psychopharmacologia</i> , Berlin, 1973, V.33,	
		64. Blasig J., Herz A., Reinhold K., Zieglgansberger S. "Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats", <i>Psychopharmacologia</i> , Berlin, 1973, V.33,	

Examiner Signature	/Jonathan Lau/	Date Considered	07/02/2009
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.87 and 1.90. The information is required to obtain or retain a benefit by the public which it is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 1.22 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<b>FORM PTO-1449B</b>		<b>Attorney Docket:</b> 4874-7000	<b>Serial No.:</b> 10/567,114
<b>INFORMATION DISCLOSURE CITATION</b>		<b>Applicant:</b> ZHILOV, et al.	
		<b>Filing Date:</b> August 4, 2003	<b>Group Art Unit:</b> T/B/A
<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	

/J.L./	64 . (cont.)	p.19-38.	
	65.	Rahman S., Ali Khan R., Kumar A. "Experimental study of the morphine de-addiction properties of Delphinium nududatum" Wall, BMC Complement Altern. Med., 2002, V.29, p.1-6.	
	66.	Misko T.R., Schilling R.J., Salvemini D. et al. "A fluorometric assay for the measurement of nitrite in biological samples". Anal. Biochem., 1993, V. 214, p.11-16.	
	67.	Lei B., Adachi N., Nagaro T., Arai T. "Measurement of total nitric oxide metabolite (NO (x) (-)) levels in vivo. Brain", Res. Protoc., 1999, V. 4, p. 415-419.	
	68.	Bredt M., Snyder S. "Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum", Proc. Natl. Acad. Sci., USA, 1989, V.86, p.9030-9033.	
	69.	Bradford M. M. "A rapid and sensitive method for quantitation of microgram quantities of protein using the principle of protein binding" Anal. Biochem., 1976, V. 72, p. 248-254.	
	70.	Giuliano F., Allard J. "Dopamine and male sexual function" Eur. Urol., 2001, 40 (6), 601-608.	
↓	71.	Giuliano F., Allard J., Rampin O. et. al. "Pro-erectile effect of systemic apomorphine: existence of a spinal site action" J. Urol., 2002, 167 (1), 402-406.	
/J.L./	72.	Brien S.E., Smallegange C., Gofton W.T., et.al. "Development of a rat model of sexual performance anxiety: effect of behavioral and pharmacological hyperadrenergic stimulation on apomorphine-induced erections" Int. J. Impot. Res., 2002, 14 (2), 107-115.	

Examiner Signature	/Jonathan Lau/	Date Considered	07/02/2009
--------------------	----------------	-----------------	------------

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.